Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$1.20
-AU$0.14(-11.97%)
At close: 4:00 PM EDT
AU$1.20
-AU$0.14(-11.97%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume503.64K
Average Volume (3M)24.03K
Market Cap
AU$37.38M
Enterprise ValueAU$15.20
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,890,478
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.60M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces financial distress risk and preserves flexibility to fund clinical programs and commercialization through equity or grants. This balance-sheet conservatism supports a multi‑month execution window and reduces bankruptcy risk while revenue scales.
Revenue GrowthSustained top-line growth indicates improving commercial traction for the OncoSil device. Continued revenue expansion supports operating leverage potential, improves bargaining power with suppliers and payers, and validates market demand in interventional oncology over the medium term.
Specialized Product MoatA focused, clinically differentiated device for locally advanced pancreatic cancer creates high technical and regulatory barriers to entry. Specialized delivery and clinical adoption needs build a durable competitive advantage and clearer pathway for reimbursement and clinician preference.
Bears Say
Negative ProfitabilityPersistently negative margins indicate the business is not yet economically scalable. Even with revenue growth, inability to reach positive gross or EBITDA margins forces ongoing capital raises, limits reinvestment, and risks dilution or strategic compromises over the coming months.
Negative Cash FlowConsistent operating and free cash outflows reduce runway and increase dependence on external financing. For a device company requiring clinical and commercial spend, negative cash flow constrains investments in sales, manufacturing scale and regulatory activities over the medium term.
Very Small TeamA headcount of six limits capacity for commercial rollout, clinical support, regulatory submissions and manufacturing scale-up. Execution risk rises when a small team must manage complex device commercialization, slowing adoption and increasing reliance on external partners.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$37.38M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 14 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,890,478 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.99%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―